Clinical Trial Update: Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5 [EARLY_Phase 1]

View source ↗

Summary

Siemens Molecular Imaging completed an exploratory Phase 0 PET imaging study of the F-18 RGD-K5 tracer. The study evaluated imaging across multiple cancers incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• High-grade Glioma
• Lung Cancer
• Melanoma
• Sarcoma

Drugs mentioned

• F-18 RGD-K5 (fluorine-18 labeled RGD-K5)

Snippet

Sponsor: Siemens Molecular Imaging | Conditions: Sarcoma, Melanoma | EARLY_Phase 1 | Status: COMPLETED